| Literature DB >> 24968332 |
Wuttikrai Sesang1, Sittiporn Punyanitya2, Siripit Pitchuanchom3, Phansuang Udomputtimekakul4, Narong Nuntasaen5, Ratana Banjerdpongchai6, Benjawan Wudtiwai7, Wilart Pompimon8.
Abstract
From ethyl acetate-methanol extracts of leaves and twigs of Pseuduvaria trimera a new aporphine alkaloid; 8-hydroxy-1,4,5-trimethoxy-7-oxoaporphine or 8-hydroxyartabonatine C (1) was isolated, together with the known 1,2,3-trimethoxy-4,5-dioxo-6a,7-dehydroaporphine (ouregidione, 2). Their structures were elucidated by a combination of spectral methods; mainly 2D NMR; IR and MS. Compounds 1 and 2 exhibited cytotoxic activity with IC50 values of 26.36±5.18 μM and 12.88±2.49 μM, respectively, for human hepatocellular carcinoma HepG2 cells, and 64.75±4.45 and 67.06±3.5 μM, respectively, for human breast cancer MDA-MB231 cells. Both compounds displayed anti-cancer activity but less than that of doxorubicin; a conventional chemotherapeutic drug, the IC50 levels of which were 2.21±1.72 and 1.83±0.09 μM for HepG2 and MDA-MB231 cells, respectively.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24968332 PMCID: PMC6270962 DOI: 10.3390/molecules19078762
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of the isolated aporphine alkaloids.
Figure 2Most important observed fragmentations for compound 1.
Figure 3NOE experiment, significant correlations in the COSY and HMBC spectra.
1H-NMR (500 MHz), 13C-NMR (125 MHz) in DMSO-d6 1 and CDCl3 for 2.
| Position | 8-Hydroxy-1,4,5-trimethoxy-7-oxoaporphine (1) | 1,2,3-Trimethoxy-4,5-dioxo-6a,7-dehydroaporphine (2) | ||||
|---|---|---|---|---|---|---|
| *
| *
| |||||
| 1 | - | 159.15 (C) | - | 158.66 (C) | ||
| 1a | - | 131.58 (C) | - | 116.26 (C) | ||
| 1b | - | 120.21 (C) | - | 120.31 (C) | ||
| 2 | 7.60
| 127.51 (CH) | - | 147.54 (C) | ||
| 3 | 7.62
| 126.87 (CH) | - | 160.44 (C) | ||
| 3a | - | 117.65 (C) | - | 117.62 (C) | ||
| 4 | - | 147.02 (C) | - | 175.41 (C) | ||
| 5 | - | 157.49 (C) | - | 157.63 (C) | ||
| 6a | - | 129.82 (C) | - | 128.38 (C) | ||
| 7 | - | 175.55 (C) | 7.83
| 116.0 (CH) | ||
| 7a | - | 119.21 (C) | - | 131.77 (C) | ||
| 8 | - | 155.80 (C) | 7.98
| 128.48 (CH) | ||
| 9 | 7.57
| 113.76 (CH) | 7.65
| 127.57 (CH) | ||
| 10 | 7.88
| 128.17 (CH) | 7.66
| 127.44 (CH) | ||
| 11 | 9.34
| 126.81 (CH) | 9.5
| 127.24 (CH) | ||
| 11a | - | 125.91 (C) | - | 121.23 (C) | ||
| 1-OMe | 4.10
| 61.09 (CH3) | 4.17
| 62.08 (CH3) | ||
| 2-OMe | - | - | 4.10
| 61.74 (CH3) | ||
| 3-OMe | - | - | 4.21
| 61.17 (CH3) | ||
| 4-OMe | 3.99
| 61.59 (CH3) | - | - | ||
| 5-OMe | 3.97
| 61.65 (CH3) | - | - | ||
| 8-OH | 12.02
| - | - | - | ||
| N-H | - | - | 11.77
| - | ||
* δ in ppm from TMS [coupling constants (J) in Hz are given in parentheses]; obsc. = obscure signal.
Figure 4Cell cytotoxicity of 1 and 2 on human hepatocellular carcinoma HepG2 cells. HepG2 cells were treated with 1 and 2 at various concentrations for 24 h and the cell viability was determined by MTT assay. * p < 0.05, compared to control of both compound 1 and 2.
Figure 5Cell cytotoxicity of 1 and 2 on human breast cancer MDA-MB231cells. MDA-MB231 cells were treated with 1 and 2 at various concentrations for 24 h and the cell viability was determined by MTT assay. * p < 0.05, compared to control of both compound 1 and 2.
IC10, IC20 and IC50 levels of compound 1 and 2 in human hepatocellular carcinoma HepG2 cells.
| Compound | HepG2 | |||||
|---|---|---|---|---|---|---|
| IC10 (μM) | IC20 (μM) | IC50 (μM) * | ||||
| MEAN | SD | MEAN | SD | MEAN | SD | |
| 4.21 *a | ±1.60 | 8.74 *a | ±2.22 | 26.36 *a | ±5.18 | |
| 1.74 *b | ±0.23 | 3.46 *b | ±1.10 | 12.88 *b,c | ±2.49 | |
| - | - | - | - | 2.21 | ±1.72 | |
* p < 0.05, a vs. control of compound 1, b vs. control of compound 2, c vs. IC50 level of compound 1.
IC10, IC20 and IC50 levels of compound 1 and 2 in human breast cancer MDA-MB231 cells.
| Compound | MDA-MB231 | ||||||
|---|---|---|---|---|---|---|---|
| IC10 (μM) | IC20 (μM) | IC50 (μM) * | |||||
| MEAN | SD | MEAN | SD | MEAN | SD | ||
| 5.02 *a | ±0.53 | 15.12 *a | ±1.24 | 64.75 *a,c | ±4.45 | ||
| 3.37 *b | ±0.88 | 8.20 *b | ±2.45 | 67.06 *b | ±3.5 | ||
| - | - | - | - | 1.83 | ±0.09 | ||
* p < 0.05, a vs. control of compound 1, b vs. control of compound 2, c vs. IC50 level of compound 2.
Figure 6Cell cytotoxicity of doxorubicin on human hepatocellular carcinoma HepG2 and breast cancer MDA-MB231 cells. HepG2 and MDA-MB231 cells were treated with doxorubicin at various concentrations for 24 h and the cell viability were determined by MTT assay. * p < 0.05, compared to control.